Expression of CLDN1 in colorectal cancer: A novel marker for prognosis

Sumiko Nakagawa, Norikatsu Miyoshi, Hideshi Ishii, Koshi Mimori, Fumiaki Tanaka, Mitsugu Sekimoto, Yuichiro Doki, Masaki Mori

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Claudin1 (CLDN1) plays an important role not only in the intercellular barrier function of tight junctions (TJs) but also in migration and invasiveness of cancer cells. Previous reports show that CLDN1 overexpression is significantly related to the malignant behavior in several cancer types whereas its significance in colorectal cancer (CRC) is not fully understood. The present study comprised 119 patients who underwent surgery for CRC, as well as 3 cell lines derived from human CRC. The correlation of gene expression with clinical parameters in patients was assessed by knockdown experiments using 3 cell lines. Patients with high CLDN1 expression were statistically shown to have a relatively better prognosis, and those with low CLDN1 expression showed poorer overall survival and disease-free survival than those with high expression. The assessment of CLDN1 knockdown in the 3 cell lines demonstrated that the siRNA inhibition resulted in a statistically significant increase in cell invasiveness. In conclusion, the present data strongly suggest that CLDN1 expression is a prognostic factor in CRC patients.

Original languageEnglish
Pages (from-to)791-796
Number of pages6
JournalInternational journal of oncology
Volume39
Issue number4
DOIs
Publication statusPublished - Oct 1 2011

Fingerprint

Colorectal Neoplasms
Cell Line
Tight Junctions
Small Interfering RNA
Disease-Free Survival
Neoplasms
Gene Expression
Survival

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Expression of CLDN1 in colorectal cancer : A novel marker for prognosis. / Nakagawa, Sumiko; Miyoshi, Norikatsu; Ishii, Hideshi; Mimori, Koshi; Tanaka, Fumiaki; Sekimoto, Mitsugu; Doki, Yuichiro; Mori, Masaki.

In: International journal of oncology, Vol. 39, No. 4, 01.10.2011, p. 791-796.

Research output: Contribution to journalArticle

Nakagawa, S, Miyoshi, N, Ishii, H, Mimori, K, Tanaka, F, Sekimoto, M, Doki, Y & Mori, M 2011, 'Expression of CLDN1 in colorectal cancer: A novel marker for prognosis', International journal of oncology, vol. 39, no. 4, pp. 791-796. https://doi.org/10.3892/ijo.2011.1102
Nakagawa, Sumiko ; Miyoshi, Norikatsu ; Ishii, Hideshi ; Mimori, Koshi ; Tanaka, Fumiaki ; Sekimoto, Mitsugu ; Doki, Yuichiro ; Mori, Masaki. / Expression of CLDN1 in colorectal cancer : A novel marker for prognosis. In: International journal of oncology. 2011 ; Vol. 39, No. 4. pp. 791-796.
@article{5f416e694f404eeb8934d13fdd7e9145,
title = "Expression of CLDN1 in colorectal cancer: A novel marker for prognosis",
abstract = "Claudin1 (CLDN1) plays an important role not only in the intercellular barrier function of tight junctions (TJs) but also in migration and invasiveness of cancer cells. Previous reports show that CLDN1 overexpression is significantly related to the malignant behavior in several cancer types whereas its significance in colorectal cancer (CRC) is not fully understood. The present study comprised 119 patients who underwent surgery for CRC, as well as 3 cell lines derived from human CRC. The correlation of gene expression with clinical parameters in patients was assessed by knockdown experiments using 3 cell lines. Patients with high CLDN1 expression were statistically shown to have a relatively better prognosis, and those with low CLDN1 expression showed poorer overall survival and disease-free survival than those with high expression. The assessment of CLDN1 knockdown in the 3 cell lines demonstrated that the siRNA inhibition resulted in a statistically significant increase in cell invasiveness. In conclusion, the present data strongly suggest that CLDN1 expression is a prognostic factor in CRC patients.",
author = "Sumiko Nakagawa and Norikatsu Miyoshi and Hideshi Ishii and Koshi Mimori and Fumiaki Tanaka and Mitsugu Sekimoto and Yuichiro Doki and Masaki Mori",
year = "2011",
month = "10",
day = "1",
doi = "10.3892/ijo.2011.1102",
language = "English",
volume = "39",
pages = "791--796",
journal = "International Journal of Oncology",
issn = "1019-6439",
publisher = "Spandidos Publications",
number = "4",

}

TY - JOUR

T1 - Expression of CLDN1 in colorectal cancer

T2 - A novel marker for prognosis

AU - Nakagawa, Sumiko

AU - Miyoshi, Norikatsu

AU - Ishii, Hideshi

AU - Mimori, Koshi

AU - Tanaka, Fumiaki

AU - Sekimoto, Mitsugu

AU - Doki, Yuichiro

AU - Mori, Masaki

PY - 2011/10/1

Y1 - 2011/10/1

N2 - Claudin1 (CLDN1) plays an important role not only in the intercellular barrier function of tight junctions (TJs) but also in migration and invasiveness of cancer cells. Previous reports show that CLDN1 overexpression is significantly related to the malignant behavior in several cancer types whereas its significance in colorectal cancer (CRC) is not fully understood. The present study comprised 119 patients who underwent surgery for CRC, as well as 3 cell lines derived from human CRC. The correlation of gene expression with clinical parameters in patients was assessed by knockdown experiments using 3 cell lines. Patients with high CLDN1 expression were statistically shown to have a relatively better prognosis, and those with low CLDN1 expression showed poorer overall survival and disease-free survival than those with high expression. The assessment of CLDN1 knockdown in the 3 cell lines demonstrated that the siRNA inhibition resulted in a statistically significant increase in cell invasiveness. In conclusion, the present data strongly suggest that CLDN1 expression is a prognostic factor in CRC patients.

AB - Claudin1 (CLDN1) plays an important role not only in the intercellular barrier function of tight junctions (TJs) but also in migration and invasiveness of cancer cells. Previous reports show that CLDN1 overexpression is significantly related to the malignant behavior in several cancer types whereas its significance in colorectal cancer (CRC) is not fully understood. The present study comprised 119 patients who underwent surgery for CRC, as well as 3 cell lines derived from human CRC. The correlation of gene expression with clinical parameters in patients was assessed by knockdown experiments using 3 cell lines. Patients with high CLDN1 expression were statistically shown to have a relatively better prognosis, and those with low CLDN1 expression showed poorer overall survival and disease-free survival than those with high expression. The assessment of CLDN1 knockdown in the 3 cell lines demonstrated that the siRNA inhibition resulted in a statistically significant increase in cell invasiveness. In conclusion, the present data strongly suggest that CLDN1 expression is a prognostic factor in CRC patients.

UR - http://www.scopus.com/inward/record.url?scp=79960858460&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960858460&partnerID=8YFLogxK

U2 - 10.3892/ijo.2011.1102

DO - 10.3892/ijo.2011.1102

M3 - Article

C2 - 21720707

AN - SCOPUS:79960858460

VL - 39

SP - 791

EP - 796

JO - International Journal of Oncology

JF - International Journal of Oncology

SN - 1019-6439

IS - 4

ER -